| Abstract | Cyclosporin A is a very powerful immunosuppressive agent. Since its introduction in 1983, it has considerably improved the renal graft survival rate. One of the main problems encountered with the use of cyclosporin A is the wide intra- and inter-patient pharmacokinetic variability found. A new microemulsion formulation of cyclosporin A (Sandimmun Neoral, Sandoz, Basel, Switzerland) has been developed. A number of clinical trials have demonstrated that the microemulsion formulation is superior to the conventional formulation in that it has a higher bioavailability and a more predicable pharmacokinetic profile. This formulation of cyclosporin A has just been introduced into Hong Kong. This article reports on the study which was designed to comfirm the safety and tolerability of switching from the conventional formulation to the microemulsion formulation in stable renal transplant patients in people's own locality. |
|---|
